Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Scpharmaceuticals Inc Market Cap
The Scpharmaceuticals Inc (SCPH) share price is expected to increase by 384.76% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered SCPH. Price targets range from $12 at the low end to $25 at the high end. The current analyst consensus for SCPH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedSCPH 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Scpharmaceuticals Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SCPH. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of SCPH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Chase Knickerbocker Craig-Hallum | Buy | $12 | Maintains | Nov 14, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | Nov 14, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | Aug 19, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | May 15, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | Mar 14, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $20 | Initiates | Sep 7, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | Aug 11, 2023 |
HC Wainwright & Co. | Buy | Reiterates | Aug 2, 2023 | |
HC Wainwright & Co. | Buy | Reiterates | Jul 19, 2023 | |
HC Wainwright & Co. | Buy | Reiterates | Jun 8, 2023 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | May 11, 2023 |
| Naz Rahman Maxim Group | Buy | $20 | Maintains | May 11, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | Mar 23, 2023 |
| Roanna Ruiz SVB Leerink | Outperform | $13 | Maintains | Jan 27, 2023 |
| Ken Cacciatore Cowen & Co. | Outperform | $25 | Initiates | Dec 1, 2022 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Maintains | Nov 10, 2022 |
| Roanna Ruiz SVB Leerink | Outperform | $12 | Maintains | Nov 10, 2022 |
| Glen Santangelo Jefferies | Buy | $14 | Assumes | Oct 21, 2022 |
| Roanna Ruiz SVB Leerink | Outperform | $11 | Upgrade | Oct 11, 2022 |
| Naz Rahman Maxim Group | Buy | Initiates | Aug 2, 2022 |
When did it IPO
2017
Staff Count
135
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. John H. Tucker
Market Cap
$180.6M
In 2023, SCPH generated $13.6M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SCPH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - scPharmaceuticals Inc. will hold its Q3 2024 Earnings Conference Call on November 13, 2024, at 4:30 PM ET, featuring key executives and financial analysts.
Why It Matters - The earnings call provides insights into scPharmaceuticals' financial performance and strategic direction, influencing stock valuation and investor sentiment.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - scPharmaceuticals reported Q3 2024 net revenue of $10 million for FUROSCIX, up 164% YoY. They received label expansion approval and completed $125 million financing, supporting future profitability.
Why It Matters - scPharmaceuticals' 164% revenue growth, label expansion approval, and successful financing signal strong potential for future profitability, enhancing investor confidence in its market position.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - ScPharmaceuticals, Inc. (SCPH) reported a Q3 loss of $0.37 per share, worse than the expected loss of $0.30, but an improvement from a loss of $0.41 per share a year prior.
Why It Matters - ScPharmaceuticals' larger-than-expected quarterly loss raises concerns about its financial health and future profitability, potentially impacting investor confidence and stock performance.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Management will host a conference call and webcast on November 13, 2024, at 4:30 p.m. ET, following market close.
Why It Matters - The scheduled conference call may provide insights into company performance, future guidance, and strategic plans, influencing investor sentiment and stock price.
Tue, 15 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A webinar will discuss a nephrologist's insights on FUROSCIX for treating fluid overload in heart failure and its potential application in chronic kidney disease.
Why It Matters - The webinar highlights FUROSCIX's clinical applications, potentially impacting its market demand and sales, which could influence stock performance of related healthcare companies.
Fri, 16 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets suggest a 291.9% upside for scPharmaceuticals (SCPH), supported by a consensus on increased earnings estimates.
Why It Matters - Analysts' targets suggest significant upside potential for scPharmaceuticals (SCPH), signaling positive sentiment and possible stock price appreciation based on revised earnings estimates.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
